SS-31 / Elamipretide Cardiolipin & Mitochondrial Research
This educational page covers scientific questions commonly searched as SS-31 peptide, elamipretide, cardiolipin, mitochondrial membrane, ATP production, oxidative stress, Barth syndrome, heart failure, kidney injury, neuroprotection and muscle/aging research. These are research topics and regulatory facts, not claims about an Avelqor research material.
What is SS-31 / elamipretide?
SS-31 is the research name widely associated with elamipretide, a mitochondria-targeting tetrapeptide. It is also known in the literature as MTP-131 or Bendavia.
Cardiolipin and inner mitochondrial membrane research
Elamipretide selectively interacts with cardiolipin, a phospholipid of the inner mitochondrial membrane. Research links this interaction to mitochondrial cristae organization, cytochrome-c function and respiratory-chain bioenergetics.
ATP and oxidative-phosphorylation research
Cardiolipin binding has been studied in relation to improved electron transport and oxidative phosphorylation. Reviews discuss increased mitochondrial bioenergetic efficiency and ATP-production capacity under experimental conditions.
Oxidative-stress research
Earlier descriptions emphasized reactive-oxygen-species reduction, while newer work focuses more broadly on membrane electrostatics, cardiolipin-dependent proteins and mitochondrial architecture. The mechanism is therefore more complex than simply “scavenging free radicals.”
Barth syndrome and FDA approval
On 19 September 2025, the U.S. FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. That approval applies to the regulated Forzinity drug product and indication; it does not confer approval, equivalence or clinical claims on separately supplied research material.
Heart, kidney, brain and muscle research
Preclinical and clinical programmes have investigated elamipretide in heart failure, ischemia-reperfusion injury, kidney injury, primary mitochondrial myopathy, ocular disease, muscle weakness and other disorders linked to mitochondrial dysfunction. Results vary by disease and study design, so these areas should be described as research programmes rather than established broad therapeutic effects.
Aging and mitochondrial function
Because mitochondrial bioenergetic decline is associated with aging, SS-31/elamipretide is frequently studied in aging and skeletal-muscle research. Much of this broader literature remains experimental.
Common SS-31 research terms
- SS-31 cardiolipin research
- elamipretide mitochondrial membrane
- SS-31 ATP and oxidative phosphorylation
- SS-31 oxidative stress
- elamipretide Barth syndrome
- SS-31 heart and kidney research
- SS-31 neuroprotection research
- SS-31 muscle and aging research
Primary research and regulatory sources
FDA: Forzinity accelerated approval · Cardiolipin and mitochondrial bioenergetics · Elamipretide mechanism and therapeutic research review
Explore Mitochondrial Signaling Research · SS-31 Documentation Guide
Research information only. This page does not provide treatment, dosing, injection or self-administration guidance and does not imply that a research material is equivalent to the FDA-approved drug product.